Spark Therapeutics has awarded an engineering, procurement and construction management contract to US-based Jacobs to build its gene therapy innovation centre in US.

The multi-storey centre, to come up in University City area of West Philadelphia, will be a key centre of excellence in the area of gene therapy manufacturing.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to Spark Therapeutics, the project will see an initial investment of $575m.

The 500,000ft2 centre is expected to be ready in 2026.

Spark had revealed its plans to set up the gene therapy innovation centre in December 2021.

It had signed a 99-year ground lease of Drexel University’s property with an aim to tap life sciences talent and bring together gene therapy experts.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The innovation facility is set to expand the company’s presence in Philadelphia. It is also expected to create options for collaboration with Drexel University and the life sciences community in Philadelphia.

Founded in 2013, Spark has been working on providing solutions to help people affected by genetic diseases ranging from blindness to neurodegenerative diseases.

Jacobs Advanced Facilities senior vice president Koti Vadlamudi said, “Our goal is to build an innovative facility that supports Spark’s mission to drive science forward.

“It will also be the first gene therapy manufacturing facility of its size in Philadelphia. We stand ready to support Spark’s vision of a world where no life is limited by genetic disease.”

So far, Jacobs has catered to over 30 clients in the field of cell and gene therapy. The company has handled various projects including production units.

—————————————————————————————————————-

Image: The 500,000ft2 centre is expected to be ready in 2026. Credit: Michal Jarmoluk from Pixabay.